Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

A groundbreaking annual injection designed to protect against Human Immunodeficiency Virus (HIV) has successfully ...

Researchers led by Imperial have unveiled primary trial results that show encouraging advances in HIV treatment driven by ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who struggle to take daily HIV pills may benefit from long-acting injectable ...

Offering mailed self-testing for HIV encouraged patients to test themselves for HIV but require methods of improving ...

To reduce care disparities and prevent them from exacerbating among people living with HIV who have long COVID, education and ...

Immunocore’s big swing for a functional HIV cure has cleared its first hurdle. | Immunocore’s big swing for a functional HIV ...

A group of leading African researchers trying to develop effective vaccines against HIV is trying to figure out how to ...

SAN FRANCISCO -- Most patients with HIV who received two broadly neutralizing antibodies (bNAbs) after pausing antiretroviral ...

Debates over tuberculosis reporting began in the late 19th century, when the bacterial infection was reframed not as a disease of the elite but of the urban poor. New York City was the first in the ...